When is Donanemab expected to be officially launched in China?

Donanemab (Donanemab, trade name: Ji Neng Da®) has been officially launched in China on March 29, 2025. On December 17, 2024, Eli Lilly announced that the drug has been approved by China’s National Medical Products Administration. FDA approval (NMPA) for the treatment of mild cognitive impairment (MCI) and mild dementia (mild) caused by Alzheimer's disease AD) Adult patients.

2025On March 31, 2025, Xuanwu Hospital and National Neurological Disease Medical Center of Capital Medical University successfully prescribed the drug for the first time in the country. 5 patients received the drug during the same period.

Donelimab is an antibody drug that targets amyloid-β. It can specifically recognize and remove amyloid-β plaques deposited in the brain, thereby slowing the progression of Alzheimer's disease. Research shows that 66% of patients achieved amyloid clearance within 1 of treatment and stopped taking the drug according to treatment recommendations. Pivotal phase 3 studies show that donexumab slowed cognitive and functional decline by up to 35%. In subjects with earlier stages of the disease, donexumab reduced the risk of disease progression by up to 39% over 18 months.

At present, donenemab has been officially launched and put into clinical use in China, and patients can obtain treatment with this drug in some medical institutions. However, it is not yet covered by medical insurance, and patients need to confirm the specific medication process and cost with the medical institution before use. With the accumulation of clinical experience and the advancement of medical insurance policies, it is expected that the accessibility of this drug will further improve in the future.

Reference materials:https://www.drugs.com/donanemab.html